Shim Kyu Hwan, Jeong Kyeong-Hoon, Bae Sun Oh, Kang Min O, Maeng Eun Ho, Choi Cheol Soo, Kim Yu-Ri, Hulme John, Lee Eun Kyu, Kim Meyoung-Kon, An Seong Soo A
Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, Seongnam-si, Republic of Korea.
Korea Mouse Metabolic Phenotyping Center, Lee GilYa Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Int J Nanomedicine. 2014 Dec 15;9 Suppl 2(Suppl 2):225-33. doi: 10.2147/IJN.S58205. eCollection 2014.
As increasing variants of nanoparticles (NPs) are being used in various products, it has become apparent that size alone can no longer adequately explain the variety of generated toxic profiles. Recent studies with NPs have suggested that various sizes of NPs could determine in vitro toxicity. In an attempt to address concerns regarding neurotoxicity of zinc oxide (ZnO) and silica (SiO2) NPs, these were examined after exposing them via oral, dermal, and intravenous administrations of NPs and their toxicological effects on the brain over a prescribed period of time were assessed. After 28 days of repeated oral administrations of ZnO or SiO2 independently, possibly due to damages to the blood brain barrier (BBB), neurotoxicity, were investigated by Evans blue technique. Next, in order to assess whether ZnO NPs could compromise the BBB, ZnO NPs were intravenously injected on day 0, 7, 14, 21 and 28 no further treatment was administered for 62 days. Deposition of SiO2 in brain from repeated dermal and oral administrations for 90 days were evaluated by transmission electron microscopy coupled with scanning energy-dispersive X-ray spectroscopy. Physiochemical profiles were principally determined on particle size at the beginning of the current toxicity investigations on ZnO and SiO2 NPs. The BBB was found to be intact after independent repeated oral administrations of ZnO or SiO2 NPs for 28 days, suggesting no significant damage. Neuronal death was also not observed after the intravenous administrations of ZnO NPs. After 90 days of repeated dermal and oral administration of SiO2 NPs, no deposition of NPs was observed in hippocampus, striatum, and cerebellum regions using transmission electron microscope analyses. These observations suggest that the BBB was not compromised and was able to block penetration of ZnO and SiO2 NPs, resulting in significant neurotoxic effects. Moreover, absence of SiO2 in three regions of brain after dermal and oral administrations for 90 days suggested that brain was protected from SiO2. No behavior change was observed in all studies, suggesting that 90 days may not be long enough to assess full neurotoxicity of NPs in vivo.
随着越来越多的纳米颗粒(NPs)变体被用于各种产品中,显而易见,仅尺寸已无法充分解释所产生的各种毒性特征。最近关于纳米颗粒的研究表明,不同尺寸的纳米颗粒可决定体外毒性。为了解决对氧化锌(ZnO)和二氧化硅(SiO2)纳米颗粒神经毒性的担忧,在通过口服、皮肤和静脉注射纳米颗粒暴露后对其进行了检查,并评估了它们在规定时间段内对大脑的毒理学影响。在分别独立重复口服ZnO或SiO2 28天后,可能由于血脑屏障(BBB)受损,采用伊文思蓝技术研究了神经毒性。接下来,为了评估ZnO纳米颗粒是否会损害血脑屏障,在第0、7、14、21和28天静脉注射ZnO纳米颗粒,在62天内不再进行进一步治疗。通过透射电子显微镜结合扫描能量色散X射线光谱法评估了90天重复皮肤和口服给药后SiO2在大脑中的沉积情况。在当前对ZnO和SiO2纳米颗粒的毒性研究开始时,主要根据粒径确定其物理化学特征。独立重复口服ZnO或SiO2纳米颗粒28天后,发现血脑屏障完好,表明没有明显损伤。静脉注射ZnO纳米颗粒后也未观察到神经元死亡。在重复皮肤和口服SiO2纳米颗粒90天后,使用透射电子显微镜分析在海马体、纹状体和小脑区域未观察到纳米颗粒的沉积。这些观察结果表明,血脑屏障未受损,能够阻止ZnO和SiO2纳米颗粒的渗透,从而产生显著的神经毒性作用。此外,在皮肤和口服给药90天后,大脑三个区域未检测到SiO2,表明大脑受到了SiO2的保护。在所有研究中均未观察到行为变化,这表明90天可能不足以评估纳米颗粒在体内的完全神经毒性。